Navigation Links
Nile Therapeutics Reports 2010 Third Quarter Financial Results
Date:11/12/2010

SAN MATEO, Calif., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for therapeutics for cardiovascular disease, today announced its third quarter financial results for 2010.

Financial ResultsFor the three months ended September 30, 2010, Nile reported a net loss of approximately $1.8 million, or $0.05 per share, compared to a net loss of approximately $2.0 million, or $0.08 per share, during the third quarter of 2009. Weighted-average shares outstanding for the third quarter were 34.6 million.

Net cash used in operating activities in the third quarter of 2010 was approximately $1.1 million. As of September 30, 2010, Nile had cash and cash equivalents of approximately $4.4 million compared to approximately $3.2 million as of December 31, 2009.

Qualifying Therapeutic Discovery Project GrantNile was recently awarded a $244,479 grant under the Internal Revenue Service's Qualifying Therapeutic Discovery Project program, which was established under the U.S. Patient Protection and Affordable Care Act of 2010.  The Company expects to receive the grant funds prior to the end of 2010.

Update on CD-NPOn November 2, Nile announced that CD-NP met the primary end-point, safety and tolerability, in an open-label, single-blind, placebo-controlled Phase 2 study of 77 patients with acute decompensated heart failure (ADHF) and renal dysfunction. Additionally, secondary analyses demonstrated favorable effects of CD-NP on renal function.

An infusion of CD-NP for up to 72 hours at doses of 1.25 and 2.5 ng/kg/min appeared to be well tolerated.  A dose-dependent effect on blood pressure was observed, with minimal or mild blood pressure reduction at 1.25 and 2.5 ng/kg/min, and moderate blood pressure reduction at 3.75 ng/kg/min.  Dose escalation was limited by
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:7/10/2014)... omega 3 fatty acids had healthier joints than those ... fatty acids, according to Duke Medicine researchers. , The ... Diseases (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that ... contribute to worsening osteoarthritis. , "Our results suggest that ... factors in the link between obesity and osteoarthritis," said ...
(Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
(Date:7/10/2014)... 2014 Best Drug Rehabilitation ... having family close by during a stay in ... or not the process is successful, has launched ... at http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success ... from several Best Drug Rehabilitation graduates who wanted ...
(Date:7/10/2014)... As the use of electronic health record becomes widespread ... implementation of the Affordable Care Act, the quantity of ... analytic purposes will also dramatically increase. Additionally, experts ... that analyze large quantities of data for the purpose ... the value of patient care a process that ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, ... hot flashes that often accompany menopause, new research suggests. ... of menopausal women, said Dr. Taraneh Shirazian, an assistant professor ... School of Medicine at Mount Sinai Hospital in New York ... hot flashes a day, and she added that hot flashes ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3
... Coaches, trainers focus on prevention, better treatment for ... -- "Getting your bell rung." "A dinger." "Knocking ... a serious problem -- a concussion. , But ... are getting a lot better at spotting a ...
... barometer - gas prices go up, major ... market trend to stay home, shop online, REDMOND, Wash., ... offering over 30,000 supplements at,savings up to 50% today announced that ... quarters of 2008 as people change shopping habits to,offset today,s high ...
... Holmes,(Amex: HH ) today announced the sale ... Claims Evaluation Division (CED), a unit providing,independent medical ... for use in evaluating claims., The sale ... purchase,price of approximately $5.6 million. In one transaction, ...
... prices, biofuels, and climate change places 1.7,billion people ... risk of hunger, warns,anti-poverty agency ActionAid., WASHINGTON, ... in Hokkaido, Japan, ActionAid launches a new report, ... Global Food Crisis and What,They Can Do to ...
... NavigatorMD, Inc., a leading,benefits intelligence, software ... of Value-Based Plan Design development, announced,the addition ... Development and,Sales., Norris brings 24 years ... including market development and management. As Director ...
... - Thyroid cancer that has spread to distant sites has ... blood vessel formation can slow disease progression in some patients, ... Texas M. D. Anderson Cancer Center reports in the July ... . , The investigational drug, motesanib diphosphate, is a VEGF ...
Cached Medicine News:Health News:Playing It Safe With High School Sports 2Health News:Playing It Safe With High School Sports 3Health News:Playing It Safe With High School Sports 4Health News:Photo: VitaminLife.com Sees Internet Sales Up 40% in Major Metro Markets as Gas Crisis Looms; Shopping Behaviors Change as People Conserve Gas 2Health News:Hooper Holmes Announces Sale of Claims Evaluation Division 2Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:Marshall Norris Joins NavigatorMD as Director of Business Development and Sales 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4
... Stryker Threaded Dilator System ... another choice for drilling ... provide compaction reaming versus ... of bone within the ...
... The USS Sports Medicine Knot Pusher is a ... arthroscopic surgery. The Knot Pusher is utilized in ... and retrieving. The two piece shaft allows the ... slot for knot pushing. The ring handle allows ...
... Arthroscopy Scissor is ideal for excising soft tissue ... in the joint. The serrated edge on the ... as hold tissue within the jaws for more ... right jaw curvatures, are the perfect tools for ...
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
Medicine Products: